Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Zoetis Inc is a drug manufacturers—specialty & generic business based in the US. Zoetis shares (ZTS) are listed on the NYSE and all prices are listed in US Dollars. Zoetis employs 10,600 staff and has a trailing 12-month revenue of around USD$6.3 billion.
Since the stock market crash in March caused by coronavirus, Zoetis's share price has had significant positive movement.
Its last market close was USD$163.55, which is 13.04% up on its pre-crash value of USD$142.23 and 81.44% up on the lowest point reached during the March crash when the shares fell as low as USD$90.14.
If you had bought USD$1,000 worth of Zoetis shares at the start of February 2020, those shares would have been worth USD$683.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,207.00.
|Latest market close||USD$163.55|
|52-week range||USD$90.14 - USD$168.96|
|50-day moving average||USD$160.928|
|200-day moving average||USD$142.8669|
|Wall St. target price||USD$173.71|
|Dividend yield||USD$0.8 (0.47%)|
|Earnings per share (TTM)||USD$3.371|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-12)||-2.97%|
|1 month (2020-09-18)||1.67%|
|3 months (2020-07-17)||13.06%|
|6 months (2020-04-17)||25.11%|
|1 year (2019-10-18)||27.65%|
|2 years (2018-10-19)||78.80%|
|3 years (2017-10-19)||149.39%|
|5 years (2015-10-19)||273.57%|
Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Zoetis shares trade at around 48x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.4624. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.7 billion.
The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$6.3 billion|
|Operating margin TTM||35.76%|
|Gross profit TTM||USD$4.4 billion|
|Return on assets TTM||11.78%|
|Return on equity TTM||59.87%|
|Market capitalisation||USD$79.3 billion|
TTM: trailing 12 months
There are currently 3.8 million Zoetis shares held short by investors – that's known as Zoetis's "short interest". This figure is 8.9% up from 3.5 million last month.
There are a few different ways that this level of interest in shorting Zoetis shares can be evaluated.
Zoetis's "short interest ratio" (SIR) is the quantity of Zoetis shares currently shorted divided by the average quantity of Zoetis shares traded daily (recently around 1.5 million). Zoetis's SIR currently stands at 2.49. In other words for every 100,000 Zoetis shares traded daily on the market, roughly 2490 shares are currently held short.
However Zoetis's short interest can also be evaluated against the total number of Zoetis shares, or, against the total number of tradable Zoetis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zoetis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Zoetis shares in existence, roughly 10 shares are currently held short) or 0.008% of the tradable shares (for every 100,000 tradable Zoetis shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zoetis.
Find out more about how you can short Zoetis stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.6
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 10/01/2020) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.72/100
Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13/100
Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.87/100
Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.
|Total ESG score||28.6|
|Total ESG percentile||49.38|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||1|
Dividend payout ratio: 21.62% of net profits
Recently Zoetis has paid out, on average, around 21.62% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.47% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0.47% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $0.8 per share.
While Zoetis's payout ratio might seem low, this can signify that Zoetis is investing more in its future growth.
Zoetis's most recent dividend payout was on 1 December 2020. The latest dividend was paid out to all shareholders who bought their shares by 20 October 2020 (the "ex-dividend date").
Over the last 12 months, Zoetis's shares have ranged in value from as little as $90.14 up to $168.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.7033. This would suggest that Zoetis's shares are less volatile than average (for this exchange).
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.